


**VIBIOSPHEN** is a French privately-owned and independent company specialized in infectious diseases. Vibiosphen offers R&D services to support **each step of the target product profile (TPP) definition**: from identifying the right indication and defining the *in vitro* efficacy of the product to proving the safety of the molecule and determining the dose or route of administration.



Services and expertise along the drug development journey and TPP



### Antimicrobial susceptibility testing and safety

- ✓ Minimal Bactericidal concentration (MBC)
- ✓ Minimal inhibitory concentration (MIC)
- ✓ Time kill curve (TKC)
- ✓ Hemolysis test
- ✓ Cytotoxicity
- ✓ Immune cells bactericidal assay
- ✓ Mechanism of action studies
- ✓ Resistance selection and characterization (Antibiogram)
- ✓ Biofilm inhibition testing
- ✓ Bacterial, viral, fungal stock production services, Virus purification and characterization
- ✓ Quantitative PCR/ Genotyping



### Model safety (mice)

- ✓ MTD (maximum tolerated dose), PK/PD, ADME



### Model efficacy (mice)

- ✓ **Gastro-intestinal** infection
- ✓ **Urinary tract** infection: pyelonephritis, acute & chronic diseases
- ✓ **Tuberculosis** acute & chronic diseases
- ✓ **Pulmonary** single & co-infection
- ✓ **Skin infection**
- ✓ **Thigh infection**
- ✓ **Septicemia**

### Organoids and 3D tissues testing

- ✓ Cytotoxicity testing
- ✓ Efficacy testing
- ✓ Organ-on-a-chip

- ✓ Biomarker quantification
- ✓ Translational model
- ✓ Primary cells healthy or pathological
- ✓ High throughput screening

**Others:** histology/tissue harvest, immunology assays (flow cytometry, ELISAs,...), bacteria editing

## Pathogens (non exhaustive)



### Bacteria

- ✓ Gram-negative and Gram positive – ESKAPE – and more
- ✓ ATCC or clinical strains including resistant bacteria strains



### Virus

- ✓ SARS-CoV-2
- ✓ Influenza H1N1
- ✓ Respiratory syncytial Virus
- ✓ Rhinovirus



### Fungi

- ✓ Candida
- ✓ Aspergillus
- ✓ Trichophyton
- ✓ Malassezia



## ADDED VALUE

- ✓ BSL 2 and **BSL3 facilities** (to handle Mycobacterium tuberculosis, coronaviruses, certain chlamydia strains...)
- ✓ **Quick turnaround time:** 4 to 6 weeks between the acceptance of the proposal and the final results
- ✓ **Custom model development**
- ✓ **Support and expertise** to identify new indications, study plan design
- ✓ **Availability, flexibility and reactivity of the team**



**Robin DUMAS**, Business Developer

Mobile : +337 827 276 23

Robin.dumas@vibiosphen.com

**Maxime FONTANIÉ**, CEO

Mobile : +336 501 553 97

Maxime.Fontanie@vibiosphen.com